The Oncology Institute, Inc. (TOI)
$
2.56
-0.04 (-1.56%)
Key metrics
Financial statements
Free cash flow per share
-0.0282
Market cap
251.9 Million
Price to sales ratio
0.5463
Debt to equity
-2.2288
Current ratio
1.6787
Income quality
0.3736
Average inventory
17.3 Million
ROE
21.0396
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The Oncology Institute, Inc., based in Cerritos, California, provides comprehensive medical oncology services across the United States, specializing in physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants, and transfusion programs, along with robust patient support. The company's stock is identified with the symbol 'TOI' in the market. With an operating income of -$60,118,000.00 the company reflects its earnings from core operations while also showcasing its efficiency through a gross profit ratio of 0.14. The cost of revenue for the company is $339,415,000.00 highlighting the associated production and operational expenses. Additionally, The Oncology Institute, Inc. earned an interest income of $0.00 indicating its financial investments and stability. Serving adult and senior cancer patients, the company effectively manages clinical trial services, including clinical trial management, palliative care programs, and stem cell transplant services, operating 67 clinic locations since its founding in 2007. Currently, the stock is affordable at $3.12 making it particularly suitable for budget-conscious investors. The stock has a high average trading volume of 1,863,933.00 indicating strong liquidity in the market. With a market capitalization of $251,856,230.00 the company is classified as a small-cap player, which allows it to be agile and responsive to industry changes. It is a key player in the Medical - Care Facilities industry, contributing significantly to the overall market landscape while belonging to the Healthcare sector, where it drives innovation and growth. This positioning highlights its commitment to advancing cancer care and optimizing treatment options for patients through both comprehensive services and strategic financial management.
Is The Oncology Institute, Inc. (TOI) a good investment?
Investing in The Oncology Institute, Inc. (TOI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is The Oncology Institute, Inc. (TOI)'s stock forecast?
Analysts predict The Oncology Institute, Inc. stock to fluctuate between $0.60 (low) and $4.88 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is The Oncology Institute, Inc.'s market capitalization?
As of 2026-02-20, The Oncology Institute, Inc.'s market cap is $251,856,230, based on 98,381,340 outstanding shares.
How does The Oncology Institute, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, The Oncology Institute, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy The Oncology Institute, Inc. (TOI) stock?
To buy The Oncology Institute, Inc. (TOI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TOI. Place an order (Market, Limit, etc.).
What is the best time to invest in The Oncology Institute, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did The Oncology Institute, Inc. perform in the last earnings report?
Revenue: $393,412,000 | EPS: -$0.71 | Growth: -22.83%.
Where can I find The Oncology Institute, Inc.'s investor relations reports?
Visit https://theoncologyinstitute.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for The Oncology Institute, Inc.?
You can explore historical data from here
What is the all-time high and low for The Oncology Institute, Inc. stock?
All-time high: $12.66 (2021-12-27) | All-time low: $0.13 (2024-11-21).
What are the key trends affecting The Oncology Institute, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its fourth quarter results on February 25, 2026.
seekingalpha.com
The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.
globenewswire.com
CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.
fool.com
The Oncology Institute has struck deals to care for cancer patients in five states, which leaves room for growth. It's currently treating nearly 2 million patients.
seekingalpha.com
The Oncology Institute, Inc. ( TOI ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO & Executive Director Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Greetings, and welcome to The Oncology Institute Third Quarter 2025 Earnings Call.
zacks.com
The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.18 per share a year ago.
globenewswire.com
CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
globenewswire.com
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2025.
zacks.com
The Oncology Institute (TOI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
seekingalpha.com
The Oncology Institute has achieved a strong growth in revenue in the previous years, justifying its stock price movement. We believe TOI will still be able to grow in the coming quarters while currently trading at a discount. Risks remain high, warranting careful positioning.
See all news
